文献速递胸部技术与安全CT

肺癌与非肺癌患者免疫检查点抑制剂相关肺炎的临床与影像学特征

Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
PubMed 文献 · Br J Radiol · 2020-08-12

该单中心回顾性研究筛查247例接受免疫检查点抑制剂治疗的恶性肿瘤患者,共识别26例免疫检查点抑制剂相关肺炎(肺癌19例、非肺癌7例)。发生肺炎者既往其他免疫相关不良事件比例更高(63% vs 34%,p=0.0056),肺癌患者发病更早(78天 vs 186天,p=0.0034),非肺癌组发病时血清KL-6显著升高(p=0.029)。CT上两组均以机化性肺炎型表现和磨玻璃影为主,肺癌组更常见实变、牵拉性支气管扩张及不对称分布(p<0.001),非肺癌组更常见对称性浸润。

要点

  • 免疫检查点抑制剂相关肺炎在肺癌患者中发病更早(78天 vs 非肺癌186天,p=0.0034)。
  • 既往有其他免疫相关不良事件者发生肺炎比例更高(63% vs 34%,p=0.0056)。
  • 肺癌组CT更常见实变、牵拉性支气管扩张及不对称分布(p<0.001),非肺癌组更常见对称性浸润。

关键影像表现/征象

  • 免疫检查点抑制剂相关肺炎的主要CT表现为机化性肺炎型表现和磨玻璃影,与原发性疾病无关。
  • 肺癌患者常见实变和牵拉性支气管扩张,且倾向于不对称阴影(p<0.001)。
  • 非肺癌患者更常表现为对称性浸润。
  • 两组均有小部分患者出现复发或游走性肺炎表现。

诊断标准与关键数值

  • 免疫检查点抑制剂相关肺炎组既往其他免疫相关不良事件发生率为63%,无肺炎组为34%(p=0.0056)。
  • 肺癌患者免疫检查点抑制剂相关肺炎发病时间为78天,非肺癌患者为186天(p=0.0034)。
  • 非肺癌组在发现免疫检查点抑制剂相关肺炎时血清KL-6显著升高(p=0.029)。
  • 肺癌组与非肺癌组CT表现不对称分布差异有统计学意义(p<0.001)。

临床应用与阅片要点

  • 接受免疫检查点抑制剂治疗的患者出现其他免疫相关不良事件时,应警惕后续发生肺炎的可能。
  • 肺癌患者免疫检查点抑制剂相关肺炎发病较早,随访中需注意时间窗。
  • 非肺癌患者肺炎诊断中血清KL-6升高可能具有参考价值。
  • 阅片时注意区分肺癌患者的不对称实变伴牵拉性支气管扩张与非肺癌患者的对称性浸润。
  • 作者建议纵向观察胸部CT以评估肺炎活动性,与癌症类型无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients.

METHODS: 247 patients (LC, n = 151) treated with ICI for malignancies were retrospectively screened in a single institute. The number of patients, history of other immune-related adverse events (irAE), the onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, laterality, location) were recorded for the ICI-P population and compared for LC and non-LC groups.

RESULTS: ICI-P was identified in 26 patients in total (LC, n = 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, irrespective of primary disease, were organizing pneumonia pattern and ground glass opacities. LC patients commonly exhibited consolidation and traction bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC patients were more likely to exhibit symmetrical infiltrations. A small fraction of both groups experienced relapse or moving patterns of ICI-P.

CONCLUSION: ICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients.

ADVANCES IN KNOWLEDGE: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Nobashi TW, Nishimoto Y, Kawata Y, et al. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol. 2020. PMID: 32783627. doi:10.1259/bjr.20200409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。